Post-restructuring, Pfizer R&D focused on its top blockbuster prospects

Posted On 08 Oct 2013
By :

Long before AstraZeneca ($AZN) and Merck ($MRK) set out to hack a billion dollars or more out of global R&D operations, Pfizer ($PFE)set the pace for research shock therapy with an effort that realigned therapeutic priorities, shed programs, shuttered facilities and demanded a much more careful pipeline strategy. But even as the pharma giant has declared the three-year R&D plan at an end, research chief Mikael Dolsten says it’s very much a work in progress as the company scrambles to advance the hottest prospects which emerge.

“There is a committed strategic funding for each therapeutic area that gives them critical mass, and then we will move resources as we see the most successful projects need them,” Dolsten told Reuters‘ senior pharma writer Ben Hirschler. “In the near-term, we see oncology, vaccines and immunology as three very strong areas … if great projects arrive, like palbociclib in breast cancer, then we will fund those projects appropriately.”

Read the source article at

About the Author

Leave a Reply